Itraconazolo Eg

Itraconazole, the active ingredient in Itraconazolo Eg, is a azole antifungal presented as an oral formulation for oral use. It treats a range of fungal infections, including dermatophyte infections, onychomycosis, blastomycosis, histoplasmosis, coccidioidomycosis and aspergillosis in adult patients.

GNH USA supplies Itraconazolo Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Itraconazole is an azole antifungal that interferes with fungal cell membrane synthesis, making it effective for several systemic and superficial mycoses. - Dermatophyte infections: resolves skin and nail infections caused by dermatophyte fungi. - Onychomycosis: clears fungal nail infections resistant to topical therapy. - Blastomycosis: treats systemic infection caused by Blastomyces dermatitidis. - Histoplasmosis: manages disseminated disease from Histoplasma capsulatum. - Coccidioidomycosis: combats infection by Coccidioides species. - Aspergillosis: used for invasive disease caused by Aspergillus spp.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes after dosing. - Abdominal pain: discomfort in the upper abdomen. - Headache: transient mild headache. - Rash: skin redness or itching. - Taste disturbance: altered taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac failure: worsening of congestive heart failure. - Visual disturbances: blurred vision or photophobia. - Severe allergic reactions: anaphylaxis or angioedema. - Peripheral edema: swelling of extremities.

Itraconazole requires careful monitoring due to its systemic effects and interaction potential. - Liver function monitoring: assess hepatic enzymes before and during therapy. - Drug interaction review: evaluate concomitant CYP3A4 substrates and inhibitors. - Pregnancy safety: contraindicated (Category D) because of fetal risk. - Breastfeeding caution: avoid use as drug is excreted in milk. - Cardiac status: use with caution in patients with heart failure. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Itraconazole has several clinically significant drug interactions that must be managed. Major Interactions (Avoid): - Rifampin: induces metabolism, markedly reducing itraconazole levels. - Ketoconazole: additive hepatotoxicity when combined. - St. John’s wort: strong CYP3A4 inducer, decreasing efficacy. Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, requiring closer coagulation monitoring. - Statins (e.g., simvastatin): increased risk of myopathy, monitor muscle symptoms.